Benzinga··Vandana SinghFDA Warns ImmunityBio Over Anktiva Cancer Claims Despite Strong 750% Sales Surge
FDA flagged ImmunityBio for unsupported Anktiva cancer cure claims. Company implemented corrective measures while reporting 750% unit volume growth and $38.29M quarterly revenue.
IBRXsales growthregulatory compliance